Search Results - "Tetrault, Tanya"
-
1
1223 Non-viral targeted knock-in of a KRAS G12D specific TCR, CD8αβ, and chimeric cytokine receptor in the TRAC locus outperforms lentiviral-based engineering of T cells
Published in Journal for immunotherapy of cancer (01-11-2023)“…BackgroundThe AFNT-212 cell therapy consists of autologous CD8+ and CD4+ T cells expressing 1) a T Cell Receptor (TCR) specific for the prevalent oncogenic…”
Get full text
Journal Article -
2
355 Directing a high avidity KRAS G12D-specific TCR engineered with a CD8αβ co-receptor and chimeric cytokine receptor using non-viral knock-in enhances anti-tumor responses
Published in Journal for immunotherapy of cancer (01-11-2023)“…BackgroundAdoptive T cell therapy has demonstrated clinical activity in a subset of patients with solid tumors; however, consistent responses will require…”
Get full text
Journal Article -
3
Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice
Published in The Journal of pharmacology and experimental therapeutics (01-11-2023)“…Pompe disease is a rare glycogen storage disorder caused by a deficiency in the lysosomal enzyme acid -glucosidase, which leads to muscle weakness, cardiac and…”
Get full text
Journal Article -
4
Abstract 10: Non-viral engineered T cell therapy specific for the hotspot mutation p53 R175H that integrates signal 1 (TCR), signal 2 (co-stimulation) and signal 3 (cytokine) and co-opts FasL-dependent apoptosis to achieve a coordinated antitumor CD4/8 T cell response
Published in Cancer research (Chicago, Ill.) (22-03-2024)“…Adoptive T cell therapy (ACT) has demonstrated antitumor efficacy in patients with solid cancers but requires further optimization to become a reproducibly…”
Get full text
Journal Article -
5
Abstract 9: AFNT-212: A TRAC -knocked-in KRASG12D-specific TCR-T cell product enhanced with CD8αβ and a chimeric cytokine receptor for treatment of solid cancers
Published in Cancer research (Chicago, Ill.) (22-03-2024)“…The KRASG12D mutation is an ideal target for anti-cancer therapies as its expression is typically clonal, restricted to cancer tissue, and is among the most…”
Get full text
Journal Article